RxDoctor Payments DataLook up a doctor →

Chi-Ying Sage

Family · Waterloo, IANPI 1831722370

Payments from drug & device makers

$14,147in general payments, 2019–2025

Across 815 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Pfizer$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Boehringer Ingelheim$621
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$14,147100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,147 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$49,317
Medicare patients
174
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$18,857
JardianceEmpagliflozin12$10,331
Pantoprazole Sodium87$1,425
Atorvastatin Calcium149$1,383
Levothyroxine Sodium86$784
Omeprazole56$736
Potassium Chloride34$731
Rosuvastatin Calcium38$613
Metoprolol Succinate50$607
Albuterol Sulfate HfaAlbuterol Sulfate27$493
Losartan Potassium40$472
Simvastatin72$459
Escitalopram Oxalate27$446
Amlodipine Besylate53$439
Fluticasone Propionate18$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,629$18,85720 claims
Boehringer IngelheimJardiance$621$10,33112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.

Other family in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →